MA27079A1 - Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes - Google Patents

Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes

Info

Publication number
MA27079A1
MA27079A1 MA27654A MA27654A MA27079A1 MA 27079 A1 MA27079 A1 MA 27079A1 MA 27654 A MA27654 A MA 27654A MA 27654 A MA27654 A MA 27654A MA 27079 A1 MA27079 A1 MA 27079A1
Authority
MA
Morocco
Prior art keywords
derivatives
naphthyridine
diabetes
treatment
related disorders
Prior art date
Application number
MA27654A
Other languages
English (en)
Inventor
Yamin Wang
William H Bullock
Libing Chen
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA27079A1 publication Critical patent/MA27079A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

DERIVES DE 1,6-NAPHTYRIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU DIABETE ET DE TROUBLES APPARENTES De manière générale, la présente invention concerne des dérivés de naphtyridine de formule: dans laquelle un des radicaux U, X, Y ou Z est un atome d'azote et les autres sont C-R, oé R est l'atome d'hydrogène ou un substituant. Plus spécifiquement, l'invention concerne des dérivés de 1,6-naphtyridine et des compositions pharmaceutiques contenant ces dérivés. Les méthodes de l'invention comprennent l'administration d'un dérivé de naphtyridine selon la présente invention en vue de traiter le diabète et des troubles apparentés.
MA27654A 2001-09-26 2004-04-23 Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes MA27079A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32451101P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
MA27079A1 true MA27079A1 (fr) 2004-12-20

Family

ID=23263913

Family Applications (2)

Application Number Title Priority Date Filing Date
MA27652A MA26344A1 (fr) 2001-09-26 2004-04-23 Derives 1,8-naphtyridine utilises comme antidiabetiques
MA27654A MA27079A1 (fr) 2001-09-26 2004-04-23 Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA27652A MA26344A1 (fr) 2001-09-26 2004-04-23 Derives 1,8-naphtyridine utilises comme antidiabetiques

Country Status (24)

Country Link
US (5) US6677352B1 (fr)
EP (2) EP1432710A1 (fr)
JP (2) JP2005504808A (fr)
KR (2) KR20040041177A (fr)
CN (2) CN1578780A (fr)
AR (2) AR037503A1 (fr)
BR (2) BR0212864A (fr)
CA (2) CA2463039A1 (fr)
CO (2) CO5560542A2 (fr)
EC (2) ECSP045084A (fr)
GT (2) GT200200191A (fr)
HN (1) HN2002000275A (fr)
HR (2) HRP20040309A2 (fr)
HU (2) HUP0401889A2 (fr)
IL (2) IL160708A0 (fr)
MA (2) MA26344A1 (fr)
MX (2) MXPA04002136A (fr)
NO (2) NO20041560L (fr)
PE (2) PE20030601A1 (fr)
PL (2) PL369567A1 (fr)
RU (2) RU2004112787A (fr)
UY (2) UY27457A1 (fr)
WO (2) WO2003027112A1 (fr)
ZA (2) ZA200403064B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
EP1467730A4 (fr) * 2002-01-22 2010-03-10 Univ California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
WO2005018567A2 (fr) * 2003-08-22 2005-03-03 Bayer Pharmaceuticals Corporation Composes et compositions pour le traitement du diabete et de troubles lies au diabete
DE602004024814D1 (de) * 2003-11-04 2010-02-04 Merck & Co Inc Substituierte naphthyridinonderivate
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
BRPI0514381A (pt) * 2004-07-30 2008-06-10 Palumed Sa compostos hìbridos de aminoquinolina-antibiótico, composições farmacêuticas, método de preparação e uso destes
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7645885B2 (en) * 2005-08-26 2010-01-12 The Regents Of The University Of California Non-steroidal antiandrogens
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (fr) 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008074068A1 (fr) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Dérivés de quinoline substitués utilisés comme agents non-amyloïdogéniques
US8063066B2 (en) * 2007-03-19 2011-11-22 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US10017827B2 (en) 2007-04-04 2018-07-10 Nidera S.A. Herbicide-resistant sunflower plants with multiple herbicide resistant alleles of AHASL1 and methods of use
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010009319A2 (fr) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
CA2741125A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
WO2011075643A1 (fr) * 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
EP2677869B1 (fr) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
CA2839395A1 (fr) * 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Composes d'aminomethyl-quinolone
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2880901A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composes tricycliques antidiabetiques
WO2014130608A1 (fr) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
CN103183676B (zh) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
WO2014164409A1 (fr) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JO3442B1 (ar) * 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
TWI748941B (zh) 2015-02-27 2021-12-11 美商英塞特公司 Ｐｉ３ｋ抑制劑之鹽及製備方法
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
BR112018002681A2 (pt) 2015-08-10 2019-04-24 Viiv Healthcare Uk No 5 Ltd ?composto, composição, e, método para tratamento de infecção por hiv?
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA038455B1 (ru) * 2016-10-26 2021-08-31 Новартис Аг Новые производные нафтиридинона и их применение в лечении аритмии
EP3551176A4 (fr) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用
KR102660894B1 (ko) * 2021-09-17 2024-04-26 기초과학연구원 피리미딘-2-아민 화합물의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US990774A (en) * 1910-03-15 1911-04-25 John W P Reid Convertible core for building-blocks.
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4616019A (en) 1984-01-26 1986-10-07 Abbott Laboratories Naphthyridine antibacterial compounds
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
US5126352A (en) 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4988705A (en) 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4810708A (en) 1986-05-15 1989-03-07 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4767762A (en) 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
CA2001203C (fr) 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Dithiocarbamoyl quinolones antimicrobiens
CA2012681A1 (fr) 1989-03-31 1990-09-30 Masayasu Okuhira Derives de la quinolone, procedes de preparation et agents antibacteriens les renfermant
JP2787713B2 (ja) * 1989-07-28 1998-08-20 富山化学工業株式会社 新規なイソチアゾローナフチリジンおよびイソチアゾローキノリン誘導体並びにそれらの塩
JP3012684B2 (ja) * 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
WO1994012499A1 (fr) 1992-12-01 1994-06-09 The Green Cross Corporation Derive de 1,8-naphthyridin-2-one et utilisation de ce derive
DE4303657A1 (de) 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
SK281341B6 (sk) 1994-06-14 2001-02-12 Dainippon Pharmaceutical Co., Ltd. Deriváty pyridónkarboxylovej kyseliny alebo jej farmaceuticky prijateľných solí, spôsob ich prípravy a farmakologické prostriedky ich obsahujúce
JP3242792B2 (ja) 1994-08-05 2001-12-25 日本臓器製薬株式会社 ナフチリジニウム誘導体
MX9701600A (es) 1994-08-29 1997-05-31 Yamanouchi Pharma Co Ltd Derivados de naftiridina novedosos y composicion medicinal de los mismos.
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
EP0841929B1 (fr) 1995-08-02 2003-05-07 Darwin Discovery Limited Quinolones et leur utilisation therapeutique
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
US6274592B1 (en) 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5994367A (en) 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
EP0958297A1 (fr) 1997-08-06 1999-11-24 Suntory Limited Derive de 1-aryl-1,8-naphtylidine-4-one utilise en tant qu'inhibiteur de phosphodiesterase de type iv
GB9720052D0 (en) 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
EP0978516A4 (fr) 1998-01-29 2001-01-10 Suntory Ltd Derives de 1-cycloalkyle-1,8-naphthyridine-4-one presentant une activite inhibitrice de la phosphodiesterase iv
KR100286874B1 (ko) 1998-03-04 2001-04-16 성재갑 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법
EP1085846A2 (fr) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
AU4694999A (en) * 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
CA2310433A1 (fr) 1998-09-18 2000-03-30 Senju Pharmaceutical Co., Ltd. Procede de solubilisation de l'acide pyridonecarboxylique, solubilisant a cet effet, preparations de solutions aqueuses contenant de l'acide pyridonecarboxylique et leur procede de production
JP2003500397A (ja) 1999-05-19 2003-01-07 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｍｒｓ阻害剤としての２−ｎｈ−ピリドンおよびピリミドン
CA2407370A1 (fr) 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles utiles en tant qu'inhibiteurs de l'enzyme impdh
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체

Also Published As

Publication number Publication date
GT200200194A (es) 2003-07-03
BR0212864A (pt) 2004-08-17
MXPA04002035A (es) 2004-06-07
PL369567A1 (en) 2005-05-02
US6677352B1 (en) 2004-01-13
CO5560611A2 (es) 2005-09-30
CO5560542A2 (es) 2005-09-30
PE20030601A1 (es) 2003-09-07
WO2003027112A1 (fr) 2003-04-03
EP1432711A1 (fr) 2004-06-30
GT200200191A (es) 2003-05-23
HRP20040309A2 (en) 2006-05-31
US20060189609A1 (en) 2006-08-24
US20040014751A1 (en) 2004-01-22
ECSP045081A (es) 2004-06-28
US20040157875A1 (en) 2004-08-12
IL160708A0 (en) 2004-08-31
JP2005504808A (ja) 2005-02-17
CA2461132A1 (fr) 2003-04-03
ECSP045084A (es) 2004-06-28
CA2463039A1 (fr) 2003-04-03
EP1432710A1 (fr) 2004-06-30
NO20041567L (no) 2004-05-11
HUP0401889A2 (hu) 2005-01-28
UY27456A1 (es) 2003-04-30
HN2002000275A (es) 2005-02-22
AR037503A1 (es) 2004-11-17
HUP0402310A2 (hu) 2005-02-28
PE20030549A1 (es) 2003-08-18
AR037504A1 (es) 2004-11-17
WO2003027113A1 (fr) 2003-04-03
ZA200403063B (en) 2005-04-22
UY27457A1 (es) 2003-04-30
KR20040041178A (ko) 2004-05-14
US20040209866A1 (en) 2004-10-21
RU2004112787A (ru) 2005-10-10
MA26344A1 (fr) 2004-10-01
MXPA04002136A (es) 2005-03-07
CN1578780A (zh) 2005-02-09
IL160707A0 (en) 2004-08-31
BR0212829A (pt) 2004-08-03
NO20041560L (no) 2004-05-11
US6964971B2 (en) 2005-11-15
CN1578781A (zh) 2005-02-09
US7109196B2 (en) 2006-09-19
RU2004112771A (ru) 2005-10-10
PL369531A1 (en) 2005-05-02
KR20040041177A (ko) 2004-05-14
HRP20040317A2 (en) 2006-06-30
ZA200403064B (en) 2005-06-29
JP2005504807A (ja) 2005-02-17
US6900205B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
MA27079A1 (fr) Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA26991A1 (fr) Triazolopyridines servant d'agents anti-inflammatoires
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
CA2126465C (fr) Inhibiteurs de restenose apres une arterioplastie coronaire percutanee
MA28271A1 (fr) Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA26879A1 (fr) Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation.
MA28438B1 (fr) Derives azabicyclo (3.1.0) hexane utiles comme modulateurs des recepteurs d3 de la dopamine
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
MA27582A1 (fr) Derives benzazepine pour le traitement de troubles neurologiques
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
DE60003220D1 (de) [1,2,3]-TRIAZOLO[4,5-d]PYRIMIDIN-DERIVATE ALS ANTITHROMBOTISCHE MITTEL
CA2171675A1 (fr) Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2332513A1 (fr) Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60137442D1 (de) 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung
MA29793B1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques.
MA26721A1 (fr) Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DE60139409D1 (de) Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen
CA2308867A1 (fr) Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent